1 November 2023 false No description of principal activity Taxfiler 2024.6 false 14210304business:PrivateLimitedCompanyLtd2023-11-012024-07-31 142103042023-10-31 142103042023-11-012024-07-31 14210304business:AuditExemptWithAccountantsReport2023-11-012024-07-31 14210304business:FilletedAccounts2023-11-012024-07-31 142103042024-07-31 14210304business:Director12023-11-012024-07-31 14210304business:RegisteredOffice2023-11-012024-07-31 142103042023-10-31 14210304core:WithinOneYear2024-07-31 14210304core:WithinOneYear2023-10-31 14210304core:ShareCapitalcore:PreviouslyStatedAmount2024-07-31 14210304core:ShareCapitalcore:PreviouslyStatedAmount2023-10-31 14210304core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-07-31 14210304core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-10-31 14210304core:PreviouslyStatedAmount2024-07-31 14210304core:PreviouslyStatedAmount2023-10-31 14210304business:SmallEntities2023-11-012024-07-31 14210304countries:EnglandWales2023-11-012024-07-31 14210304core:FurnitureFittings2023-11-012024-07-31 14210304core:ComputerEquipment2023-11-012024-07-31 14210304core:FurnitureFittings2023-10-31 14210304core:ComputerEquipment2023-10-31 14210304core:FurnitureFittings2024-07-31 14210304core:ComputerEquipment2024-07-31 142103042022-07-022023-10-31 iso4217:GBP xbrli:pure
Company Registration No. 14210304 (England and Wales)
S.RAGNO PHARMA CONSULTING LTD Unaudited accounts for the period from 1 November 2023 to 31 July 2024
S.RAGNO PHARMA CONSULTING LTD Unaudited accounts Contents
Page
- 2 -
S.RAGNO PHARMA CONSULTING LTD Company Information for the period from 1 November 2023 to 31 July 2024
Director
S Ragno
Company Number
14210304 (England and Wales)
Registered Office
FLAT 502 10 CUTTER LANE LONDON SE10 0XX ENGLAND
Accountants
Richard Matthew Accountancy Ltd Milner Cowfold Road Coolham West Sussex RH13 8QJ
- 3 -
S.RAGNO PHARMA CONSULTING LTD Statement of financial position as at 31 July 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
- 
2,583 
Current assets
Debtors
239,449 
- 
Cash at bank and in hand
- 
312,796 
239,449 
312,796 
Creditors: amounts falling due within one year
- 
(73,014)
Net current assets
239,449 
239,782 
Net assets
239,449 
242,365 
Capital and reserves
Called up share capital
1 
1 
Profit and loss account
239,448 
242,364 
Shareholders' funds
239,449 
242,365 
For the period ending 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 31 July 2024 and were signed on its behalf by
S Ragno Director Company Registration No. 14210304
- 4 -
S.RAGNO PHARMA CONSULTING LTD Notes to the Accounts for the period from 1 November 2023 to 31 July 2024
1
Statutory information
S.RAGNO PHARMA CONSULTING LTD is a private company, limited by shares, registered in England and Wales, registration number 14210304. The registered office is FLAT 502 10 CUTTER LANE, LONDON, SE10 0XX, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous period, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
20% straight line
Computer equipment
1/3rd straight line
Going concern
The company has ceased trading and the director's intention is to liquidate the company.
4
Tangible fixed assets
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 November 2023
1,353 
2,251 
3,604 
Disposals
(1,353)
(2,251)
(3,604)
At 31 July 2024
- 
- 
- 
Depreciation
At 1 November 2023
271 
750 
1,021 
On disposals
(271)
(750)
(1,021)
At 31 July 2024
- 
- 
- 
Net book value
At 31 July 2024
- 
- 
- 
At 31 October 2023
1,082 
1,501 
2,583 
- 5 -
S.RAGNO PHARMA CONSULTING LTD Notes to the Accounts for the period from 1 November 2023 to 31 July 2024
5
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
Other debtors
239,449 
- 
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
VAT
- 
587 
Taxes and social security
- 
66,339 
Loans from directors
- 
4,988 
Accruals
- 
1,100 
- 
73,014 
7
Average number of employees
During the period the average number of employees was 0 (2023: 0).
- 6 -